Tag: CX 2025

CX 2025: “Robust” patency seen at six months in FLEX First...

Six-month outcomes of the FLEX First arteriovenous (AV) registry, assessing the safety and efficacy of the Flex vessel prep (VP) system (VentureMed) in combination...

CX 2025: Sirolimus implant fails to meet fistula maturation endpoint in...

Results of the ACCESS 2 study, evaluating arteriovenous fistula (AVF) outcomes following use of the Sirogen (Vascular Therapies) sirolimus-eluting collagen implant, have shown that...

‘Lively’ debate anticipated during CX Vascular Access and Renal Interventions session

A dedicated all-day session at CX 2025 (Wednesday 23 April, Auditorium 3) will address critical challenges in vascular access and renal interventions, featuring multiple...